Molecular hybridization approach was used to synthesize substituted 2-(2-(4-aryl oxy benzylidene)
hydrazinyl)benzo thiazole derivatives with 2-hydrazinobenzothiazole and 4-(alicycli/aryl/biaryl/heteroaryl
oxy)benzaldehyde as new anti-TB agents. The synthesized compounds, when tested against H37Rv strains of Mtb using
Resazurin Microtitre Assay (REMA) method, showed promising activity (MIC 1.35-36.50μg/mL). 6-chloro-2-(2-(4-
(pyridin-4-yloxy) benzylidene) hydrazinyl) benzo[d]thiazole (10v) gave MIC of 1.35 μg/mL. Thus making it, a potential
lead could be developed for further antitubercular studies.
采用分子杂交的方法合成了取代的2-(2-(4-芳氧苯亚甲基)
肼基)苯
噻唑衍
生物,以2-
肼基苯
噻唑和4-(饱和环/芳香族/二
芳烃/杂
芳烃氧)
苯甲醛作为新的抗结核药物。在用Resazurin微孔实验法(R
EMA)对H37Rv株的结核分枝杆菌进行测试时,合成化合物显示出良好的活性(最低抑菌浓度MIC为1.35-36.50μg/mL)。6-
氯-2-(2-(4-(
吡啶-4-氧)苯亚甲基)
肼基)苯并[d]
噻唑(10v)的MIC为1.35μg/mL。因此,它可以作为进一步抗结核研究的潜在候选药物。